The efficacy of combined Albendazole and Praziquantel therapy versus Albendazole monotherapy in treatment of parenchymal neurocysticercosis: A systematic review

Gaurav Nepal¹, Jessica Holly Rehrig², Rajan Sharma Kandel¹, Shaik Tanveer Ahamad³, Bipin Kandel¹, Rajeev Ojha¹, Jayant Kumar Yadav¹, Sujan Jamarkattel⁴, Ravi Shah¹, Jeevan Gautam¹, Gentle Sunder Shrestha¹

¹Maharajgunj Medical Campus, Tribhuvan University Teaching Hospital, Maharajgunj, Kathmandu, Nepal;
²Department of Neurology, North Shore University Hospital, NY, United States;
³Deccan College of Medical Sciences, Hyderabad, India;
⁴Tufts Medical Centre, Boston, MA, United States.

Keywords: Albendazole, neurocysticercosis, praziquantel

Introduction

The World Health Organization (WHO) estimates that about 2.56–8.30 million individuals worldwide are suffering from neurocysticercosis (NCC), making it the most common parasitic disease of the central nervous system (CNS). The Center of Disease Control (CDC) has classified NCC as one of the five neglected parasitic infections (NPIs) due to the minimal attention this widely prevalent condition has received from public, clinical, and research communities. NCC occurs due to the ingestion of the eggs of the parasite Taenia solium, which

Abstract

Preliminary studies suggest combined albendazole and praziquantel (ABZ+PZQ) therapy has superior anti-parasitic effect compared to albendazole (ABZ) or praziquantel (PZQ) monotherapy, due to potential pharmacokinetic synergism. We thus present an evidence-based review evaluating the risks and benefits associated with combination ABZ+PZQ therapy compared to standard ABZ monotherapy in the treatment of viable parenchymal Neurocysticercosis (NCC). Our systematic review is based on PRISMA (Preferred Reporting Items for Systematic review and Meta-Analysis) statement. Our primary outcome measure was to compare the efficacy of ABZ+PZQ with ABZ alone for treatment of NCC. Efficacy was determined based on clinical and radiographic evaluation. The secondary outcome measured the incidence of adverse effects in each treatment group. Literature search yielded a total of 120 articles. After excluding duplicates and those not meeting inclusion criteria, five papers were reviewed for data collection. Medication regimens, number of cyst, patient age, and location varied amongst included papers. The combination therapy resulted in significant symptom and cyst resolution in patients with more than two viable parenchymal cysts as compared to monotherapy. The two treatment arms were comparable in treating NCC with low cyst burden. There was no significant difference in the adverse effects between two treatment groups. In individuals with multi-cystic NCC, the patients who received dual therapy had better outcomes than those who received ABZ monotherapy as evidenced by radiographic improvement and reduced seizure episodes. The adverse effect profile in patients receiving dual therapy was similar and comparable to those with monotherapy.
is capable of cysticerci formation in various human organs. It is the leading global cause of preventable epilepsy and accounts for 30% of all cases in Latin America, Asia, and Africa.

The cysticerci pass through three stages within the central nervous system: viable (vesicular), non-viable (colloidal and granular), and calcified. When a cyst transitions from viable to non-viable form, an associated inflammatory response is identified in the surrounding cortex, leading to clinical manifestations such as headache, nausea, vomiting, dizziness, stroke, psychiatric symptoms, and severe intracranial hypertension.6,7 After a cyst dies, the dystrophic calcified area acts as a focal point for seizure activity. If left untreated, it may lead to complications such as epilepsy, hydrocephalus, cerebral herniation and death.4 The MRI features of parenchymal neurocysticercosis is given in Figure 1.

Therapy is largely anchored in antiparasitic agents, most commonly albendazole (ABZ) or praziquantel (PZQ).1,4 ABZ acts by binding to the colchicine-sensitive portion of tubulin, inhibiting assembly of cytoplasmic microtubules necessary for glucose uptake in larval and adult forms of the parasite. PZQ disrupts calcium ion homeostasis in the worm and the current consensus is that it antagonizes voltage-gated calcium channels. It is hypothesized that disruption of these channels results in uncontrolled calcium ion influx leading to uncontrolled muscle contraction and paralysis.4 In addition to the antiparasitic therapy, corticosteroids and anti-epileptics are used to mitigate perilesional edema and treat seizures respectively.10

Guidelines around the world support the use of ABZ for active NCC. However, recently, combination therapy with PZQ has generated significant interest among clinicians. Combined albendazole and praziquantel (ABZ+PZQ) therapy has shown to have potential pharmacokinetic synergism by increasing plasma concentrations of albendazole sulfoxide,12 albendazole sulfone, albendazole sulphone and PZQ metabolites.8 Apart from NCC, the ABZ+PZQ combination has been used successfully in the treatment of other parasitic conditions, including hydatid disease6,11 and schistosomiasis.12

To date, only a few studies have been published directly comparing ABZ+PZQ dual therapy to ABZ monotherapy in the treatment of viable parenchymal NCC. Extrapolation of existing data is limited by the small sample size of the studies.6,13-16 We aim to present a substantial evidence-based review of the studies evaluating the risks and benefits associated with combined ABZ+PZQ therapy compared to ABZ monotherapy in viable parenchymal NCC.

**Methods**

Our systematic review utilized the PRISMA (Preferred Reporting Items for Systematic review and Meta-Analysis) statement in conjunction with the PRISMA checklist and flow diagram for manuscript format development.17

**Literature search**

The following databases served as sources for published studies prior to June 2019: PubMed, Google Scholar and China National Knowledge Infrastructure (CNKI). Searches were conducted using the keywords “combined albendazole and praziquantel”, “albendazole and praziquantel”, and “albendazole plus praziquantel” in combination with “neurocysticercosis” or “NCC”. Titles, abstracts, and full text were screened for the study and report characteristics that matched eligibility criteria. Two authors (RSK and GN) screened, retrieved, and excluded reports. An additional investigator (JR) participated in the review process when eligibility uncertainty arose.

**Eligibility criteria**

The study must be carried out on human subjects, distinctly state the study design, sample size, inclusion criteria, baseline characteristics of the patients, and drug dosage administered. It should compare ABZ+PZQ with ABZ alone in patients with viable parenchymal NCC and have reported clinical and/or radiological outcomes following therapy. Studies across all languages were included.

**Data extraction**

Data was manually extracted from the eligible studies by the research investigators. The following variables were included: first author, type of design, site of study, year of publication, sample size, doses of drugs, concomitant therapy, mean age of participants, male to female ratio of participants, baseline number of cysts identified on imaging, follow-up, outcomes and adverse effects of medications.

**Outcome measures**

Our primary outcome measure was to compare the efficacy of ABZ+PZQ with ABZ alone for treatment of NCC. Efficacy was based upon clinical and radiographic improvement. The secondary outcome measured the incidence of adverse effects in each treatment group.

**Results**

In total, our literature search yielded 120 articles. After excluding duplicates and those not meeting inclusion criteria, five papers were reviewed for data collection. Figure 2 displays the results of our literature search and selection. The characteristics of each study are summarized in Table 1 and Table 2.

**Study characteristics:**

Two of the five studies were non-randomized trials11,14 and the remaining three utilized a randomized, double-blinded, placebo-controlled methodology.8,11,16 Date of publications ranged from 2001-2016, and were conducted in India, China,11,14 and Peru15,16 respectively. In all included studies, ABZ+PZQ combined therapy was compared with ABZ monotherapy. Xu et al. had 40 subjects in the ABZ+PZQ and 631 in ABZ group.14 Guo et al. had 30 subjects in each group,15 while Kaur et al. had 53 subjects in the ABZ+PZQ and 50 in the ABZ arm.8 In 2014, Garcia et al. conducted a phase 3 study with 39 ABZ+PZQ and 41 ABZ subjects.16 In 2016, Garcia et al. published their phase 2 trial data with 16 subjects in each group.15 Baseline patient characteristics are tabulated in Table 2. There was some variability in age in the study population. Xu et al.14 and Guo et al.11 both the trials from China, had set no age limitation for inclusion in their studies. Kaur et al. focused on pediatric patients,6 while Garcia et al. (2014)10 and Garcia et al. (2016)16 included adult patients only.

**Drugs and Doses:**

**Combined Albendazole-praziquantel:**

Combined therapeutic regimens varied in dosage and frequency across the reviewed studies. Xu et al. administered ABZ 20 mg/kg/day for 12 days, followed by PZQ 30 mg/kg/day for 12 days as a course, with two courses in total given with a two to three-month intermission period in between.14 Guo et al. used a cumulative dose of 100 mg/kg for ABZ and PZQ, respectively, over two to four weeks.15 Kaur et al. administered ABZ 15 mg/kg/day for seven days and PZQ 75 mg/kg/day for one day. Garcia et al. (2014) and Garcia et al. (2016) followed a 10-day regimen of ABZ (15 mg/kg per day) combined with PZQ (50 mg/kg/day).15,16

**Combined Albendazole and Praziquantel therapy versus Albendazole monotherapy in treatment of parenchymal neurocysticercosis: A systematic review**
**Albendazole alone:**

Medication dosage and frequency was variable in the control arm as well. Xu et al. started a course of ABZ at 15 mg/kg/day for 15 days and repeated the course after a two to three-month intermission period. Guo et al. followed a total dose of ABZ 200 mg/kg over two to four weeks. Kaur et al. administered ABZ at 15 mg/kg/day for seven days. Garcia et al. (2014) and Garcia et al. (2016) used ABZ 15 mg/kg/day for ten days.14

**Concomitant therapy:**

Xu et al. did not mention concomitant therapy used during antiparasitic treatment of neurocysticercosis. Guo et al. utilized neuroprotective agents, anti-epileptics and drugs to reduce the raised intracranial pressure, as necessary. Kaur et al. managed patients with oral prednisolone (2 mg/kg/day), for the first five days of treatment, and carbamazepine dosed at 12 to 15 mg/kg/day. Garcia et al. (2014) and Garcia et al. (2016) used the following as concomitant therapy: an anti-epileptic (phenytoin or carbamazepine), dexamethasone 0.1 mg/kg/day in divided doses (morning and evening), and 300 mg/day of ranitidine.13,16

**End-point assessment:**

Xu et al. expressed the results in the form of a short-term effective rate, which was calculated using the criteria set by Ma Yunxiang et al.16 The rate was based on clinical evaluation and CT/MRI results following one year of therapy. Guo et al. documented pre-therapy predominant symptoms such as headache and seizure and MRI findings and compared them following therapy, as an indicator for treatment efficacy. A symptom-score difference of ≥ 1 and an MRI indicating the resolution of ≥75% of lesions was assumed to be effective based on the criteria. Kaur et al. compared the treatment group CT imaging characteristics at the 1, 3, and 6 month follow ups and seizure recurrence rates at 1-year. Garcia et al. (2014) primarily reviewed differences in complete MRI cyst resolution at 6 months. Other outcomes were the proportions of resolved cysts between study groups, the effect of complete cyst resolution on seizure frequency, and the number of cysts remaining after antiparasitic treatment. Garcia et al. (2016) only looked for cysticidal efficacy (i.e. the proportion of cysts resolved) using a baseline and follow-up MRI after six months of treatment.16

**Efficacy of the therapy:**

Xu et al.’s short-term effective rates after one year of therapy was 55.0% for ABZ and 98.1% for ABZ+PZQ (p<0.01). Guo et al. concluded that 46.7% in the ABZ arm reported to have improvement in both clinical and radiological manifestations, compared to 80.8% in the ABZ+PZQ arm (p=0.03). Seizures were controlled in 43.3% of ABZ group compared to a higher percentage of control at 76.7% in the ABZ+PZQ group (p=0.027). MRI lesion improvement was seen in 50% patients in the former group and 86.7% in the latter (p=0.006). Kaur et al. included only NCC cases with single cystic lesions in their study. Complete resolution of CT brain lesions at one, three, and six months was higher in ABZ+PZQ dual therapy (35%, 60%, and 72% respectively) versus ABZ monotherapy (25%, 42%, and 52.0% respectively) with no statistical significance (p=0.05). Delayed or non-resolution of lesions and calcification of lesions respectively was lower in the ABZ+PZQ group compared to ABZ patients at follow-up, but this was not statistically significant (p > 0.05).4

In the 2014 study by García et al., the proportion of patients with complete cyst resolution in MRI at 6 months was significantly higher at 64% in the ABZ+PZQ combination group compared to 37% in the standard ABZ group (p=0.014). The proportion of patients with complete cyst resolution was similar between treatment arms for patients with one and two cysts. However, for patients with three or more cysts, complete cyst resolution was significantly higher in the combination group compared with those in the standard ABZ group (p=0.007) or increased ABZ group (p=0.016). ABZ+PZQ dual therapy resolved more cysts than did standard ABZ (P<0.0001) or increased ABZ (p=0.0005). No significant difference existed (p=0.792) in seizure frequency during days 1–60 of treatment with dual therapy (46%) versus standard albendazole (39%) versus high-dose albendazole (45%) or during days 61–180 (p=0.624) with seizure frequency seen at 26%, 17% and 24% respectively for the aforementioned regimes. The 2016 study by García et al. found that cysticidal efficacy was higher in the ABZ+PZQ group (95%) than in the ABZ group (30%) (p<0.001). The cysticidal efficacy of ABZ+PZQ therapy was significantly increased in patients with three or more cysts than in those with one or two cysts (p<0.001). Similarly, the proportion of patients with complete cyst clearance was higher in the ABZ+PZQ group (75%) compared to those in the ABZ group (25%).16

**Adverse Effects of the therapy:**

Xu et al. reported the following adverse effects of antiparasitic therapy: fever, headache and dizziness, seizure, raised transaminase, transient unconsciousness, fundus edema/hemorrhage, limb numbness and urticaria. The incidence of adverse effects in the ABZ+PZQ group was high compared to ABZ group, and as the course of treatment progressed, adverse reactions gradually reduced. Guo et al. found that no significant adverse reactions occurred in either group. However, they measured the intracranial pressure of their patients which was found to be higher in the ABZ+PZQ group (2.02 ± 0.43) kPa in comparison to the ABZ group (1.83 ± 0.54) kPa, although the findings were not significant (p = 0.27). Kaur et al. found that both ABZ and PZQ were well tolerated in the study population. There were no reports of epigastric discomfort or other gastrointestinal sequelae. Three children in the ABZ+PZQ group and two in ABZ group developed headache on day 3 to 4 of treatment, which lasted for 1 to 2 days. Signs of raised intracranial pressure were not recorded in any patient during or after therapy. No participants in the study required withdrawal of medication as a result of adverse effects. In the study carried out by García et al. (2014), no significant differences in severe adverse effects existed between groups. Headache was noted in three (7%) patients on ABZ+PZQ group and two (5%) receiving ABZ. Drug-induced hepatitis occurred in one (2%) patient assigned to the ABZ group. García et al. (2016) found no serious side effects within the entire study population. They accessed the hematologic and biochemical profiles of all participants and found no statistical difference between the patients receiving ABZ+PZQ and those receiving ABZ.18

**Discussion**

In this systematic review, we compared the efficacy and safety of combined ABZ+PZQ therapy versus ABZ alone in viable parenchymal NCC, and found the former is more efficacious than the latter in achieving symptom and radiographic lesion resolution in multi-cystic NCC. There was no significant difference between dual and monotherapy side effect profiles. All but Kaur et al. found that dual therapy significantly increased the likelihood of symptom and radiographic lesion resolution.
compared to ABZ alone.\textsuperscript{7} With dual therapy, we theorize that higher plasma concentrations of medication would have led to increased parasitic cell death and a greater therapeutic benefit. Garcia et al. (2014) however challenged this theory. In their study, they also used an additional high-dose ABZ treatment group. The results showed that although increasing the ABZ dose was more effective than the standard ABZ regimen, it did not achieve the efficacy of combined ABZ plus PZQ. This suggests the additional cysticidal effect of PZQ is synergistic to ABZ and outperforms ABZ monotherapy alone.\textsuperscript{11}

Current recommendations suggest considering dual therapy for parenchymal NCC when two or more viable cystic lesions are present on imaging.\textsuperscript{1,3} This follows the 2014 and 2016 studies published by Garcia et al. that found that combination therapy was superior to monotherapy for resolving symptoms and radiographic evidence of NCC only in patients with three or more viable parenchymal cysts.\textsuperscript{1,3,16} It seems that the synergistic effects of dual therapy pose a therapeutic advantage only with a certain threshold of cyst burden. Further research is warranted to establish why this is so.

Kaur et al. used only mono-cystic cases of NCC in children and concluded that combination therapy with ABZ+PZQ is comparable to ABZ monotherapy in cyst resolution and seizure prevention.\textsuperscript{1} A consideration for future research would involve increasing the duration of dual therapy in mono-cystic NCC cases, as two treatment groups in Kaur et al. differed only by 1 day of Praziquantel 75 mg/kg.\textsuperscript{6} This could determine whether ABZ+PZQ therapy is therapeutically superior or equivalent to ABZ monotherapy in the treatment of NCC with a low cyst burden (i.e. patients with radiologic evidence of only one or two parenchymal cysts).

Multiple case reports and case series have proven the effectiveness of ABZ+PZQ in the treatment of NCC. Petrov et al. successfully treated NCC using a 14-day course of ABZ+PZQ without any observed side effects. The patient had complete cysticercid eradication on imaging and full resolution of concomitant symptoms.\textsuperscript{19} Huang et al. treated 478 cases of NCC using PZQ (20 mg/kg per day) and ABZ (20 mg/kg per day) intermittently. One-year follow-up revealed an effective cure rate of 96.9%.\textsuperscript{20} Li et al. treated 1830 NCC patients with similar dosing and frequency as Huang et al. and found that after three courses, 64.0% (1171) patients were cured. Of the remaining population, 25.1% (459) improved significantly, 9.1% (167) improved and 1.8% (33) did not respond to treatment. Overall efficacy for Li's study was tabulated as 98.2%.\textsuperscript{21}

Similarly, Wang et al. treated 2539 cases of NCC with ABZ 20 mg/kg daily for 12 days, followed by 12 days of PZQ 30 mg/kg daily. After an intermission of two to three months, the ABZ dose and frequency was repeated, followed by an increased dose of PZQ (50 mg/kg per day) for 15 days. The second regimen was repeated once or twice more after a paralleled period of interlude. After three to four courses of treatment, Wang et al. found 94.5% (1349/1427) of epileptic seizures were controlled. In 96.3% (861/894) of the cases, symptoms such as headache, nausea, and vomiting subsided, and of those with memory impairment, 93.3% (223/239) recovered completely. Imaging revealed complete cyst resolution in 82.9% cases, with only 17.1% (433/2539) of CT/MRI showing calcifications.\textsuperscript{22} These case reports and case series demonstrate the efficacy in ABZ+PZQ dual therapy which was also seen in this systematic review.

Our systematic review has several limitations. Firstly, there are only a few studies with direct comparisons between combined ABZ+PZQ and ABZ monotherapy in NCC. Between these studies, there are significant differences in patient characteristics, treatment regimen and presentation of results. We were thus unable to perform a meta-analysis to evaluate the effectiveness of combined regimen. Moreover, most of the included studies have a small sample size, making it difficult to extrapolate data.

Despite this, this study is, to the best of our knowledge, the first systematic review comparing the efficacy of combined ABZ+PZQ with ABZ monotherapy in the treatment of NCC. Our literature search was comprehensive and included publications across all languages. Additionally, our analysis includes a diverse patient population (Indian, South American, Chinese descent). It is essential that the evidence obtained from our study be applied on a large scale, across different populations worldwide, to reaffirm our findings.

**Conclusion**

ABZ+PZQ dual therapy is more efficacious than ABZ monotherapy in the pharmacotherapeutic management of viable parenchymal multi-cystic NCC both in terms of symptom and radiographic lesion resolution. The side effect profile is similar in both groups. More studies with comparable brain lesions with similar treatment regimens are warranted.

**Abbreviations**

NCC: Neurocysticercosis

ABZ: Albendazole

PZQ: Praziquantel

ABZ+PZQ: Combined albendazole and praziquantel

CT: Computed tomography

MRI: Magnetic resonance imaging

PRISMA: Preferred Reporting Items for Systemic review and Meta-Analysis

CDC: Center of Disease Control

NPI: Neglected parasitic infections

**Declarations:**

**Acknowledgments**

None

**Authors' contributions**

GN, GSS, RSK and JHR designed the study. GN, RSK and JHR carried out literature search, review, and selection. GN, JHR, STA, BK, RS, JG and SJ analyzed the selected literatures and synthesized the results. GN, RS, STA, BK, YKS and JR drafted the manuscript. GN, YKS, JKY, RO, GSS and JHR were involved in revising the manuscript critically for important intellectual content. All authors read and approve the final manuscript.

**Funding**

We received no funds for conducting this study.

**Availability of data and materials**

No data sets were created in this study

**Ethics approval and consent to participate**

Not applicable for this kind of paper

**Consent for publication**

Not applicable.

**Competing interests**

None
None of the authors has any conflict of interest to disclose. We confirm that we have read the journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

References

1. WHO. Landscape analysis: management of neurocysticercosis with an emphasis on low- and middle-income countries. 2015. Available from: https://apps.who.int/trs/portal/index/10665/152996
The efficacy of combined Albendazole and Praziquantel therapy versus Albendazole monotherapy in treatment of parenchymal neurocysticercosis: A systematic review

Figure 1: Magnetic resonance imaging (MRI) of a 22 years old male who presented with generalized tonic-clonic seizure. Various MRI sequences and contrast study suggested for Neurocysticercosis.

A: MRI brain T2-weighted axial image showing a lesion with a hyperintense cystic wall with central low signal intensity in the right parietal lobe. There is a T2 high signal intensity area surrounding the lesion, suggestive of perilesional edema.

B: MRI brain T2-weighted coronal image showing two lesions with a hyperintense cystic wall with central low signal intensity in the right parietal lobe. There is a T2 high signal intensity area adjacent to the lesions, suggestive of perilesional edema.

C: MRI brain FLAIR axial image showing low signal intensity lesion with surrounding high signal intensity in the right parietal lobe suggestive of a cyst with perilesional edema.

D: Post-gadolinium T1-weighted axial MRI brain showing a ring-enhancing lesion containing a hyperintense dot in the right parietal lobe.

Figure 2: PRISMA flow diagram displaying the results of our literature search and selection

Table 1: Key methodological characteristics of included studies.

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Country</th>
<th>Study design</th>
<th>Treatment groups: n (%)</th>
<th>Drug doses</th>
<th>Concomitant therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xu et al[14]</td>
<td>2001</td>
<td>China</td>
<td>Non-randomized trial</td>
<td>40 631</td>
<td>ALB 20 mg/kg daily for 12 days, following PZQ 30 mg/kg daily for 12 days as a course and with two courses, the intermittence was 2 to 3 months</td>
<td>15 mg/kg daily for 15 days as a course and with two courses, and the intermittence was 2 to 3 months Not mentioned</td>
</tr>
<tr>
<td>Guo et al[15]</td>
<td>2003</td>
<td>China</td>
<td>Non-randomized trial</td>
<td>30 30</td>
<td>The total dosages of ALB and PZQ were 100 mg/kg, respectively. Course of treatment was 2 to 4 weeks.</td>
<td>200 mg/kg total dose. Course of treatment was 2 to 4 weeks</td>
</tr>
</tbody>
</table>
ALB 15 mg/kg/day for 7 days and PZQ 75 mg/kg/day for 1 day

15 mg/kg/day for 7 days

Oral prednisolone (2 mg/kg/d) for the initial 5 days.
Carbamazepine 12 to 15 mg/kg/day

10 days of combined ALB (15 mg/kg per day) plus PZQ (50 mg/kg per day)

15 mg/kg per day for 10 days

Phenytoin or carbamazepine, dexamethasone at 0.1 mg/kg/d, divided into 2 doses (morning and evening), and 300 mg/d of ranitidine

PZQ at 50 mg/kg/day and ABZ 15 mg/kg/d, both for 9 and half days

ABZ 15 mg/k/day for 9 and half days

Phenytoin or carbamazepine, dexamethasone at 0.1 mg/kg/d, divided into 2 doses (morning and evening), and 300 mg/d of ranitidine

Table 2: Characteristics of patients included in selected studies.

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Age (Mean ± SD)</th>
<th>Male to female ratio</th>
<th>Number of cysts at baseline (Mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>ALB+PZQ</td>
<td>ALB</td>
<td>ALB+PZQ</td>
</tr>
<tr>
<td>Xu et al14</td>
<td>2001</td>
<td>35.89 ±16</td>
<td>1.6</td>
<td>Not available</td>
</tr>
<tr>
<td>Guo et al13</td>
<td>2003</td>
<td>36.8 ± 11.4</td>
<td>37.5±10.9</td>
<td>2</td>
</tr>
<tr>
<td>Kaur et al16</td>
<td>2009</td>
<td>7.2 ± 0.76</td>
<td>7.3 ± 0.84</td>
<td>1.9</td>
</tr>
<tr>
<td>Garcia et al15</td>
<td>2014</td>
<td>34 ± 14</td>
<td>35 ±13</td>
<td>1.73</td>
</tr>
<tr>
<td>Garcia et al16</td>
<td>2016</td>
<td>29.3 ± 9.7</td>
<td>27.5 ± 11.0</td>
<td>1.45</td>
</tr>
</tbody>
</table>

PZQ: Praziquantel; ALB: Albendazole